Neurodegenerative disease

Izabella Pena is a postdoc in Whitehead Institute Member David Sabatini’s lab investigating how toxic proteins associated with neurodegeneration are degraded in cells. We sat down with Pena to learn more about her and her experiences in and out of the lab.

Michael Gallagher is a postdoc working jointly in the labs of Whitehead Institute Founding Member Rudolf Jaenisch and Whitehead Institute Member Richard Young investigating gene regulation in neurodegenerative diseases.

Monther Abu-Remaileh is a postdoc in Whitehead Institute Member David Sabatini’s lab investigating the organelles that cells use to remove waste and recycle nutrients. We sat down with Abu-Remaileh to learn more about him and his experiences in and out of the lab.

Whitehead Institute researchers have determined how the master transcriptional regulator of the heat shock response, known as heat shock factor 1 (HSF1), is controlled in yeast. Understanding how HSF1 works, how it is regulated, and how to fine tune it in a cell-type specific way could lead to therapies for cancer and neurodegenerative diseases.

Whitehead Institute scientists have used a yeast cell-based drug screen to identify a class of molecules that target the amyloid-β (Aβ) peptide involved in Alzheimer’s disease (AD).  

Whitehead Institute researchers have determined that the lipid storage disorder Niemann-Pick type C1 (NPC1) disease is caused not only by defects in cholesterol processing but also in autophagy—a key cellular degradation pathway that malfunctions in many neurodegenerative diseases.

A team of researchers from Whitehead Institute and Sanford-Burnham Research Institute has brought new clarity to the picture of how gene-environmental interactions can kill nerve cells that make dopamine. The study uses patient-derived stem cells to show that a mutation in the α-synuclein gene causes increased vulnerability to pesticides, leading to Parkinson’s disease.

Using a discovery platform whose components range from yeast cells to human stem cells, Whitehead Institute scientists have identified a novel Parkinson’s disease drug target and a compound capable of repairing neurons derived from Parkinson’s patients.